102 related articles for article (PubMed ID: 7167065)
1. Effect of clindamycin on cytotoxin production by Clostridium difficile.
Nakamura S; Mikawa M; Tanabe N; Yamakawa K; Nishida S
Microbiol Immunol; 1982; 26(11):985-92. PubMed ID: 7167065
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological aspects of Clostridium difficile in a pediatric hospital and its role in diarrheal disease.
Camorlinga-Ponce M; Gamboa M; Barragan JJ; Munoz O; Fekety FR; Torres JF
Eur J Clin Microbiol; 1987 Oct; 6(5):542-6. PubMed ID: 3436315
[TBL] [Abstract][Full Text] [Related]
3. Effect of antibiotics on toxin production and viability of Clostridium perfringens.
Stevens DL; Maier KA; Mitten JE
Antimicrob Agents Chemother; 1987 Feb; 31(2):213-8. PubMed ID: 2882731
[TBL] [Abstract][Full Text] [Related]
4. [Rate of isolation of "C. difficile" from stools of hospitalized patients: susceptibility of 75 strains (author's transl)].
Tytgat F
Ann Microbiol (Paris); 1980; 131B(1):11-20. PubMed ID: 7458111
[TBL] [Abstract][Full Text] [Related]
5. Toxin production of Clostridium difficile in sub-MIC of vancomycin and clindamycin alone and in combination with ceftazidime.
Zarandi ER; Mansouri S; Nakhaee N; Sarafzadeh F; Moradi M
Microb Pathog; 2017 Jun; 107():249-253. PubMed ID: 28286152
[TBL] [Abstract][Full Text] [Related]
6. [Morphological changes in human embryonic lung fibroblasts caused by cytotoxins of various Clostridium species].
Schallehn G; Wolff MH
Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Jan; 267(3):367-78. PubMed ID: 3376617
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of Clostridium difficile from different sources.
Nakamura S; Nakashio S; Mikawa M; Yamakawa K; Okumura S; Nishida S
Microbiol Immunol; 1982; 26(1):25-30. PubMed ID: 7087801
[TBL] [Abstract][Full Text] [Related]
8. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxin and enterotoxin production by Clostridium difficile.
Gianfrilli P; Luzzi I; Pantosti A; Occhionero M; Gentile G; Panichi G
Microbiologica; 1984 Oct; 7(4):375-9. PubMed ID: 6513801
[TBL] [Abstract][Full Text] [Related]
10. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
Freeman J; Baines SD; Saxton K; Wilcox MH
J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
[TBL] [Abstract][Full Text] [Related]
11. Production and release of toxins A and B by Clostridium difficile.
Ketley JM; Haslam SC; Mitchell TJ; Stephen J; Candy DC; Burdon DW
J Med Microbiol; 1984 Dec; 18(3):385-91. PubMed ID: 6389875
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of beta-lactams, clindamycin and metronidazole on Clostridium difficile].
Sedallian A; Debrueres J; Roudon T; Deronzier M
Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):682-4. PubMed ID: 3054747
[TBL] [Abstract][Full Text] [Related]
13. Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice.
Mahe S; Corthier G; Dubos F
Infect Immun; 1987 Aug; 55(8):1801-5. PubMed ID: 3610315
[TBL] [Abstract][Full Text] [Related]
14. Correlation between cytotoxin production and sporulation in Clostridium difficile.
Kamiya S; Ogura H; Meng XQ; Nakamura S
J Med Microbiol; 1992 Sep; 37(3):206-10. PubMed ID: 1518037
[TBL] [Abstract][Full Text] [Related]
15. Effect of toxins produced by various Clostridium difficile strains on cecum size reduction in gnotobiotic mice.
Mahé S; Corthier G
Can J Microbiol; 1988 Jul; 34(7):916-8. PubMed ID: 3143476
[TBL] [Abstract][Full Text] [Related]
16. Clostridium difficile in gnotobiotic mice.
Onderdonk AB; Cisneros RL; Bartlett JG
Infect Immun; 1980 Apr; 28(1):277-82. PubMed ID: 7380566
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxin production by Clostridium sordellii strains.
Nakamura S; Tanabe N; Yamakawa K; Nishida S
Microbiol Immunol; 1983; 27(6):495-502. PubMed ID: 6633300
[TBL] [Abstract][Full Text] [Related]
18. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing.
Clabots CR; Peterson LR; Gerding DN
J Infect Dis; 1988 Oct; 158(4):731-6. PubMed ID: 2844914
[TBL] [Abstract][Full Text] [Related]
20. Correlation between serogroup and susceptibility to chloramphenicol, clindamycin, erythromycin, rifampicin and tetracycline among 308 isolates of Clostridium difficile.
Delmée M; Avesani V
J Antimicrob Chemother; 1988 Sep; 22(3):325-31. PubMed ID: 3053559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
